AMBALALSA · NSE
Ambalal Sarabhai Enterprises Limited
₹47.74
+3.07% (+₹1.42)
Prev. close
₹46.32
Volume
2,45,815
Delivery %
43.9%
As of
20 Aug 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Ambalal Sarabhai Enterprises Limited
Ambalal Sarabhai Enterprises Limited, together with its subsidiaries, manufactures and markets pharmaceutical, molecular diagnostics, and electronic products in India and internationally. The company is involved in the supply of pharmaceutical preparations, such as finished dosage forms and active pharmaceutical ingredients; manufacture of fermentation-based pharmaceutical products; and manufacturing and marketing analytical, laboratory, and test and measuring instruments. It also engages in the marketing and distributing professional broadcast, video, and audio equipment; marketing of generic and veterinary formulations; provision of a portfolio of products, including oncology, fertility, women's healthcare, and other specialty therapeutic segments; and manufacturing and marketing of vitamin C coated products. Ambalal Sarabhai Enterprises Limited was incorporated in 1977 and is based in Ahmedabad, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Kartikeya Vikram Sarabhai M.A.
Headquarters
Ahmedabad
Website
ase.lifeExchange
View on NSE ↗Key stats
Market cap
₹296.19 Cr
P/E ratio (TTM)
21.8
EPS (TTM)
₹1.77
Beta (5Y monthly)
-0.02
Shares float
4.69 Cr
EPS · quarter ended Jun 2026
₹0.52
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (consolidated), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.4% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹163.64 Cr | ₹196.75 Cr | ₹169.64 Cr | ₹172.94 Cr | ₹195.31 Cr | ₹200.99 Cr | |
| EBITDA | ₹28.79 Cr | ₹66.91 Cr | ₹20.31 Cr | ₹15.92 Cr | ₹13.08 Cr | ₹26.50 Cr |
| ₹29.35 Cr | ₹47.22 Cr | ₹11.45 Cr | ₹5.68 Cr | ₹4.93 Cr | ₹17.80 Cr | |
| Diluted EPS | ₹3.83 | ₹6.16 | ₹1.49 | ₹0.74 | ₹0.64 | ₹2.32 |
Depreciation & amortisation, Pretax income, Tax provision, Interest expense have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹210.05 Cr | ₹230.50 Cr | ₹245.74 Cr | ₹249.52 Cr | ₹271.68 Cr | ₹281.13 Cr | |
| ₹27.94 Cr | ₹26.75 Cr | ₹45.20 Cr | ₹46.11 Cr | ₹50.89 Cr | ₹56.53 Cr | |
| Stockholders' equity | ₹73.90 Cr | ₹119.87 Cr | ₹130.92 Cr | ₹136.42 Cr | ₹139.97 Cr | ₹158.36 Cr |
CWIP, Others have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹5.72 Cr | ₹8.89 Cr | ₹-17.62 Cr | ₹13.40 Cr | |
| Investing cash flow | — | — | ₹-16.78 Cr | ₹-5.30 Cr | ₹13.26 Cr | ₹-10.25 Cr |
| — | — | ₹9.09 Cr | ₹-2.95 Cr | ₹-1.52 Cr | ₹-1.85 Cr | |
| Capital expenditure | — | — | ₹-20.67 Cr | ₹-2.91 Cr | ₹-2.72 Cr | ₹-6.06 Cr |
| End cash position | — | — | ₹10.13 Cr | ₹10.78 Cr | ₹4.89 Cr | ₹6.19 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,846.4 | 37.1 | 5.37 | 13.7% | 0.06 | +11.9% | +12.3% |
| Divi's Laboratories Limited | ₹2.48 L Cr | ₹9,624 | 84.9 | 14.81 | 15.3% | 0.00 | +12.3% | +59.0% |
| Torrent Pharmaceuticals Limited | ₹1.88 L Cr | ₹4,985 | 78.8 | 22.38 | 25.8% | 1.79 | +21.5% | +36.5% |
| Apollo Hospitals Enterprise Limited | ₹1.28 L Cr | ₹8,835.5 | 61.5 | 13.52 | 20.5% | 0.90 | +15.7% | +14.2% |
| Lenskart Solutions Limited | ₹1.20 L Cr | ₹686.7 | 181.0 | 13.70 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.16 L Cr | ₹1,170.1 | 25.9 | 4.28 | 18.6% | 0.46 | +18.4% | +12.0% |
| Cipla Limited | ₹1.12 L Cr | ₹1,384.1 | 33.2 | 3.25 | 11.3% | 0.02 | +2.1% | -10.3% |
| Laurus Labs Limited | ₹1.09 L Cr | ₹2,034 | 99.7 | 20.52 | 16.8% | 0.48 | +22.0% | +123.5% |
| Max Healthcare Institute Limited | ₹1.02 L Cr | ₹1,066.6 | 70.4 | 9.50 | 13.4% | 0.32 | +19.0% | -8.0% |
| Dr. Reddy's Laboratories Limited | ₹1.01 L Cr | ₹1,211.2 | 30.5 | 2.68 | 11.4% | 0.21 | +3.2% | -7.4% |
| Manipal Health Enterprises Limited | ₹99,126.82 Cr | ₹760.95 | 150.7 | 11.76 | 7.8% | 1.53 | +18.0% | — |
| Ambalal Sarabhai Enterprises Limited | ₹296.19 Cr | ₹47.74 | 21.8 | 1.87 | 11.2% | 0.36 | +2.9% | — |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 30
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Ambalal Sarabhai Enterprises Ltd. (AMBALALSA) Share Price Falls 8.95% Today
Univest · 1 month ago